Impact of concomitant acid suppressive therapy on pazopanib efficacy and dose reductions in patients with metastatic renal cell carcinoma.

Greet Van De Sijpe Benoit Beuselinck Tine Van Nieuwenhuyse Roxanne Poncelet Oliver Bechter Maarten Albersen Eduard Roussel Marcella Baldewijns Tack Jan Isabel Spriet

Published in: European journal of clinical pharmacology (2020)

In this limited patient series, no evidence of a negative impact of PPI/H2RA on clinical outcome and time to first dose reduction was observed. These results suggest that PPI/H2RA might be considered, when there is a clinical need, in patients treated with pazopanib for mRCC. However, a prospective study is warranted to confirm these results.

Keyphrases

metastatic renal cell carcinoma
rheumatoid arthritis
protein protein
disease activity
ankylosing spondylitis
case report
small molecule
systemic lupus erythematosus
mesenchymal stem cells
replacement therapy